Table 1 Select demographics, select clinical comorbidities, and APOE e4 genotype status distribution of the study participants, divided by Alzheimer’s Disease Neuropathologic Change (ADNC) (n = 131)
From: Machine learning quantification of Amyloid-β deposits in the temporal lobe of 131 brain bank cases
No/Not ADNC (n = 16) | Low ADNC (n = 30) | Intermediate ADNC (n = 23) | High ADNC (n = 62) | P value | |
|---|---|---|---|---|---|
Demographic/Clinical data | |||||
Age at death (years), mean (SD) | 85.9 (10.2) | 86.9 (8.0) | 86.7 (6.5) | 84.0 (7.9) | 0.31£ |
Education attainment (years), mean (SD) | 14.3 (4.0) | 12.9 | 15.5 (3.6) | 14.8 (3.5) | 0.063£ |
Gender, (% female), N (%) | 7 (43.8%) | 16 (53.3%) | 12 (52.2%) | 29 (46.7%) | 0.89† |
Race / Ethnicity, N (%) | |||||
African American | 2 (12.5%) | 9 (30%) | 0 (0%) | 7 (11.3%) | 0.034§ |
Asian | 0 (0%) | 0 (0%) | 3 (13%) | 3 (4.8%) | |
Hispanic | 2 (12.5%) | 4 (13.3%) | 2 (8.7%) | 4 (6.5%) | |
Non-Hispanic White | 12 (75%) | 17 (56.7%) | 18 (78.3%) | 48 (77.4%) | |
APOE e4, Positive, N (%) | 4 (26.7%) | 4 (14.3%) | 5 (22.7%) | 36 (63.2%) | < 0.001§ |
Diabetes, N (%) | 5 (31.2%) | 13 (43.3%) | 5 (21.7%) | 10 (16.1%) | 0.040 |
Hypertension, N (%) | 14 (87.5%) | 26 (86.7%) | 20 (87.0%) | 46 (74.2%) | 0.386 |
Hyperlipidemia, N (%) | 13 (81.2%) | 23 (76.7%) | 15 (65.2%) | 45 (72.6%) | 0.721 |
Most Recent Assessment, N (%) | |||||
Not Demented | 6 (37.5%) | 13 (44.8%) | 3 (13%) | 1 (1.6%) | < 0.001§ |
Demented | 6 (37.5%) | 11 (37.9%) | 16 (69.6%) | 58 (93.5%) | |
Mild Cognitive Impairment | 4 (25%) | 5 (17.2%) | 4 (17.4%) | 3 (4.8%) | |
Thal Amyloid Phase | |||||
A0 (Thal Phase 0) | 16 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | < 0.001§ |
A1 (Thal Phase 1 or 2) | 0 (0%) | 26 (86.7%) | 2 (8.7%) | 0 (0%) | |
A2 (Thal Phase 3), N (%) | 0 (0%) | 2 (6.7%) | 11 (47.8%) | 0 (0%) | |
A3 (Thal Phase 4 or 5), N (%) | 0 (0%) | 2 (6.7%) | 10 (43.5%) | 62 (100%) | |
Braak NFT stage | |||||
B0 (Braak Stage 0), N (%) | 2 (12.5%) | 0 (0%) | 0 (0%) | 0 (0%) | < 0.001§ |
B1 (Braak Stage I or II), N (%) | 9 (56.3%) | 18 (60%) | 0 (0%) | 0 (0%) | |
B2 (Braak Stage III or IV), N (%) | 5 (31.3%) | 12 (40%) | 19 (82.6%) | 0 (0%) | |
B3 (Braak Stage V or VI), N (%) | 0 (0%) | 0 (0%) | 4 (17.4%) | 62 (100%) | |
CERAD score for density of neocortical neuritic plaques | |||||
C0 (No neuritic plaques) | 16 (100%) | 10 (33.3%) | 0 (0%) | 0 (0%) | < 0.001§ |
C1 (Sparse neuritic plaques) | 0 (0%) | 17 (56.7%) | 3 (13.0%) | 0 (0%) | |
C2 (moderate neuritic plaques) | 0 (0%) | 3 (10%) | 11 (47.8%) | 14 (22.6%) | |
C3 (frequent neuritic plaques) | 0 (0%) | 0 (0%) | 9 (39.1%) | 48 (77.4%) | |